New combo therapy shows promise for rare gut and lung cancers
NCT ID NCT03290079
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a combination of two drugs—pembrolizumab (Keytruda) and lenvatinib (Lenvima)—in 20 people with advanced neuroendocrine tumors that had worsened despite prior treatments. The goal was to see if the combination could shrink tumors or slow disease progression. Participants received pembrolizumab by IV and lenvatinib by mouth every three weeks. The study measured how many patients responded, how long the response lasted, and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pembrolizumab (Keytruda) and Lenvatinib (Lenvima)
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with advanced neuroendocrine tumors that have stopped responding to other therapies.
- What could go wrong
- This is a small, early-phase trial with only 20 participants, so results may not apply broadly. The combination may cause significant side effects and may not improve outcomes enough to warrant further study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a black seed extract boost immunotherapy against a rare cancer?
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
- Can a Three-Drug cocktail shrink Hard-to-Treat neuroendocrine tumors?
- Experimental combo aims to tackle Treatment-Resistant cancers
- New drug cocktail aims to shrink Hard-to-Treat gut tumors